retatrutide clinical trial weight loss Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Effects of once-weekly subcutaneous retatrutide
Description
Diabetes Care (2022) 45:157483
doi: 10.3389/fphar.2024.1416985 [DOI] [PMC free article] [PubMed] [Google Scholar] 110.Walker DK
Coaching depth: Weekly coaching, dietitian, and mental health support are included in every plan tier, not sold as add-ons
Variants in FTO rs9939609 and MC4R rs17782313 may correlate with baseline metabolism and appetite regulation, providing additional context beyond standard clinical assessment
Extended data figures and tables Extended Data Fig
